35084-69-6

Upstream product

• 15761-38-3 L-N-Boc-Ala 
• 16652-71-4 benzyl (2S)-2-pyrrolidinecarboxylate hydrochloride 
• 3392-05-0 Boc-Ala-O-N-hydroxysuccinimide 
• 543-27-1 isobutyl chloroformate 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 100-51-6 benzyl alcohol 
• 16357-59-8 N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline 

Downstream Products

• 62361-31-3 H-Ala-Pro-OBZL 
• 41591-35-9 benzyl (L)-alanyl-(L)-prolinate hydrochloride 
• 249302-44-1 Boc-Asp(O-2-Ada)-Ala-Pro-OBzl 
• 249302-46-3 Boc-Lys(2-Adoc)-Asp(O-2-Ada)-Ala-Pro-OBzl 
• 168764-14-5 Boc-Glu(O-cHex)-Lys(2-Adoc)-Asp(O-2-Ada)-Ala-Pro-OH 
• 249302-47-4 Boc-Glu(O-cHex)-Lys(2-Adoc)-Asp(O-2-Ada)-Ala-Pro-OBzl 

Relevant academic research and scientific papers

Glycopeptide derivatives for the preservation and protection of biological materials and microorganisms

The present invention relates to a compound of the following formula (I): in which at least one and only one group chosen among R5, R6 and R7 is a group of the following formula: The present invention relates also to uses

Cyclic Peptidic Mimetics of Apollo Peptides Targeting Telomeric Repeat Binding Factor 2 (TRF2) and Apollo Interaction

Telomeric repeat binding factor 2 (TRF2) is a telomere-associated protein that plays an important role in the formation of the 3′ single strand DNA overhang and the "T loop", two structures critical for the stability of the telomeres. Apollo is a 5′-exonu

Levorotatory meptazinol prodrug as well as preparation method and purpose thereof

The invention provides a levorotatory meptazinol prodrug as well as a preparation method and a purpose thereof, wherein the levorotatory meptazinol prodrug is a compound as shown in a formula I or a stereoisomer, a geometrical isomer, a tautomer, oxynitride, a hydrate, a solvate, a metabolite or a pharmaceutically acceptable salt of the compound as shown in the formula I. The compound is low in hepatic first pass effect and high in bioavailability; a medicine which uses the compound as an active component can be used for treating a neurodegenerative disease or various kinds of acute and chronic pain, such as a wound, postoperative, obstetrical and cancer pain, hemicrania, neuropathic pain and the like.

A lanthanide(III) triflate mediated macrolactonization/solid-phase synthesis approach for depsipeptide synthesis

The effect of dysprosium(III) triflate on macrolactonization reactions to form depsipeptides using MNBA (Shiina's reagent) is reported. Improved yields were obtained for the formation of 16-membered depsipeptides using lanthanide triflate additives. The use of a macrocyclization strategy permits the use of a semiautomated solid-phase synthesis approach for the rapid synthesis of analogues of the antibacterial A54556 acyldepsipeptides in only two physical operations, requiring only final product purification after cyclization.

N-bromosuccinimide oxidation of dipeptides and their amino acids: Synthesis, kinetics and mechanistic studies

Dipeptides (DP), namely valyl-glycine (Val-Gly), alanyl-proline (Ala-Pro), and valyl-proline (Val-Pro) were synthesized by classical solution phase methods and characterized. The kinetics of oxidation of amino acids (AA) and DP by N-bromosuccinimide (NBS) was studied in the presence of perchlorate ions in acidic medium at 28°C. The reaction was followed spectrophotometrically at λmax = 240 nm. The reactions follow identical kinetics, being first order each in [NBS], [AA], and [DP]. No effect on [H+], reduction product [succinimide], and ionic strength was observed. Effects of varying dielectric constant of the medium and addition of anions such as chloride and perchlorate were studied. Activation parameters have been computed. The oxidation products of the reaction were isolated and characterized. The proposed mechanism is consistent with the experimental results. An apparent correlation was noted between the rate of oxidation of AA and DP.

Amino acids and peptides. LIV. Application of 2-adamantyl derivatives as protecting groups to the synthesis of peptide fragments related to Sulfolobus solifataricus ribonuclease. I

The 2-adamantyloxycarbonyl group was employed for the protection of the ε-amino group of Lys and the hydroxyl group of Tyr, and the 2-adamantyl ester was employed for the protection of the β-carboxyl group of Asp in order to construct eight peptide segments as building blocks for the preparation of peptide fragments related to the sequence of Sulfolobus solifataricus Ribonuclease. The usefulness of the above protecting groups developed in our laboratory was confirmed.

Peptidase inhibitors

This invention relates to analogs of peptidase substrates in which the amide group containing the scissile amide bond of the substrate peptide has been replaced by an activated electrophilic ketone moiety. These analogs of the peptidase substrates provide specific enzyme inhibitors for a variety of proteases, the inhibition of which will have useful physiological consequences in a variety of disease states.

Synthesis of O-Glycopeptides of the N-Terminus of Interleukin-2

The synthesis of a number of O-glycopeptides with different lengths of chain of between 3 and 10 amino acids that are part of the N-terminus of interleukin-2 is described.The key intermediate for the syntheses is O-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranosyl)-N-(9-fluorenylmethoxycarbonyl)-L-threonine tert-butyl ester (9b), to which suitably protected amino acids and peptides can be added C- or N-terminally. 9b is an element, which allows to insert glycosylated hydroxyamino acids with the Fmoc/tBu combination of protective groups, which are approved in peptide synthesis.During the syntheses peptide blocks are used.With the deprotected products it is possible to test the structural specificity of glycosyl transferases.

Amino acid derivatives, methods of preparing said derivatives and antihypertensive drugs containing them

The present invention relates to an amino acid derivative represented by the formula STR1 wherein R1 and R2 represent hydroxyl, alkyloxy, aryloxy, arylkyloxy, alkyl, aryl, or aralkyl; R3, R5, R8 and R

Amino acid derivatives and antihypertensive drugs containing them

N-terminal phosphorus dipeptides having antihypertensive properties are disclosed.